US group suggests way to boost access to trial data while preventing misuse

BMJ 2013; 347 doi: http://dx.doi.org/10.1136/bmj.f6389 (Published 22 October 2013)
Cite this as: BMJ 2013;347:f6389

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Susan Mayor
  1. 1London

A working group convened by the Multiregional Clinical Trials Center at Harvard University has recommended a new approach to ensuring that clinical trial sponsors make participant level data publicly available while protecting against inappropriate use of the data.1

It said that one way to achieve this might be with an independent board that oversaw data requests and use. Anyone using the data would have to follow a scientifically valid analytical plan.

Michelle Mello, professor of law and public health at the Harvard School of Public Health and the report’s lead author, said, “Our experiences with Vioxx [rofecoxib], Avandia [rosiglitazone], and other widely prescribed drugs that were revealed to have serious safety risks show how important it is to give independent scientists access to clinical trial data.

“The question is: how can we achieve the powerful public health benefits of data sharing while protecting research participants’ privacy, avoiding ‘junk science,’ …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL